Substrate dependence of angiotensin I-converting enzyme inhibition: Captopril displays a partial selectivity for inhibition of N-acetyl-seryl- aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I

Molecular Pharmacology

Volumn 51, Issue 6, 1997, Pages 1070-1076

  Michaud, Annie ^a   Williams, Tracy A ^a   Chauvet, Marie Thérèse ^a   Corvol, Pierre ^a  

^a l'alimentation et l'Environnement   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN I; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRILAT; LISINOPRIL; SERASPENIDE;

ANIMAL CELL; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR FUNCTION; CELL PROTECTION; CHO CELL; DOSE RESPONSE; DRUG POTENCY; ENZYME INHIBITION; ENZYME SUBSTRATE; HEMATOPOIETIC STEM CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0030981239     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.51.6.1070     Document Type: Article

References (33)

1. Hooper, N. M. Angiotensin converting enzyme: implications from molecular biology for its physiological functions. Int. J. Biochem. 23:641-647 (1991).
2. Soubrier, F., F. Alhenc-Gélas, C. Hubert, J. Allegrini, M. John, G. Tregear, and P. Corvol. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc. Natl. Acad. Sci. USA 85:9386-9390 (1988).
3. Lattion, A.-L., F. Soubrier, J. Allegrini, C. Hubert, P. Corvol, and F. Alhenc-Gelas. The testicular transcript of the angiotensin I-converting enzyme encodes for the ancestral, non-duplicated form of the enzyme. FEBS Lett. 252:99-104 (1989).
4. Dubreuil, P., P. Fulcrand, M. Rodriguez, H. Fulcrand, J. L, and J. Martinez. Novel activity of angiotensin-converting enzyme hydrolysis of cholecystokinin and gastrin analogues with release of the amidated carboxy-terminal dipeptides. Biochem. J. 262:125-130 (1989).
5. Skidgel, R., and E. Erdös. Novel activity of human angiotensin I converting enzyme: release of the NH2- and COOH-terminal tripeptides from the luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA 82: 1025-1029 (1985).
6. Skeggs, L. T., J. R. Kahn, and N. P. Shumway. Preparation and function of the hypertensin converting enzyme. J. Exp. Med. 103:295-299 (1956).
7. Yang, H., E. Erdös, and Y. Levin. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim. Biophys. Acta 214:374-376 (1970).
8. Roques, B. P., F. Noble, V. Daugé, M. C. Fournié-Zaluski, and A. Beaumont. Neutral endopeptidase 24-11: structure, inhibition and experimental and clinical pharmacology. Pharmacol. Rev. 45:87-146 (1993).
9. Ksander, G., M. Erion, A. Yan, C. G. Diefenbacher, L. El-Chehabi, D. Cote, and N. Levens. Dual angiotensin converting enzyme/thromboxane synthase inhibitors. J. Med. Chem. 37:1823-1832 (1994).
10. Rousseau, A., A. Michaud, M.-T. Chauvet, M. Lenfant, and P. Corvol. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J. Biol. Chem. 270:3656-3661 (1995).
11. Azizi, M., A. Rousseau, E. Ezan, T.-T. Guyene, S. Michelet, J.-M. Grognet, M. Lenfant, P. Corvol, and J. Ménard. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J. Clin. Invest. 97:839-844 (1996).
12. Volpert, O. V., W. F. Ward, M. W. Lingen, L. Chesler, D. B. Solt, M. D. Johnson, A. Molteni, P. J. Polverini, and N. P. Bouck. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J. Clin. Invest. 98:671-679 (1996).
13. Jaspard, E., L. Wei, and F. Alhenc-Gélas. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II): studies with bradykinin and other natural peptides. J. Biol. Chem. 268:9498-9503 (1993).
14. Wei, L., E. Clauser, F. Alhenc-Gélas, and P. Corvol. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J. Biol. Chem. 267:13398-13405 (1992).
15. Cheung, H.-S., F.-L. Wang, M.-A. Ondetti, E. Sabo, and D. Cushman. Binding of peptide substrates and inhibitors of angiotensin-converting enzyme: importance of the COOH-terminal dipeptide sequence. J. Biol. Chem. 255:401-407 (1980).
16. Wei, L., F. Alhenc-Gélas, P. Corvol, and E. Clauser. The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J. Biol. Chem. 266:9002-9008 (1991).
17. Beldent, V., A. Michaud, L. Wei, M.-T. Chauvet, and P. Corvol. Proteolytic release of human angiotensin-converting enzyme: localization of the cleavage site. J. Biol. Chem. 268:26428-26434 (1993).
18. Cushman, D., and H. Cheung. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem. Pharmacol. 20:1637-1648 (1971).
19. Wei, L., F. Alhenc-Gélas, F. Soubrier, A. Michaud, P. Corvol, and E. Clauser. Expression and characterization of recombinant human angiotensin I-converting enzyme: evidence for a C-terminal transmembrane anchor and for a proteolytic processing of the secreted recombinant and plasma enzymes. J. Biol. Chem. 266:5540-5546. (1991).
20. Alhenc-Gélas, F., J. Weare, R. Johnson, and E. Erdös. Measurement of human converting enzyme levels by direct radioimmunoassay. J. Lab. Clin. Med. 101:83-96 (1983).
21. Bieth, J.-G. Theoretical and practical aspects of proteinase inhibition kinetics. Methods Enzymol. 248:59-84 (1995).
22. Guigon, M., D. Bonnet, F. Lemoine, L. Kobari, C. Parmentier, and J. Y. Mary. Inhibition of human bone marrow progenitors by the synthetic tetrapeptide AcSDKP. Exp. Hematol. 18:1112-1115 (1990).
23. Lombard, M. N., D. Sotty, J. Wdzieczak-Bakala, and M. Lenfant. In vivo effect of the tetrapeptide, N-acetyl-Ser-Asp-Lys-Pro on the G1-S transition of rat hepatocytes. Cell Tissue Kinet. 23:99-103 (1990).
24. Volkov, L., P. Quere, F. Coudert, L. Comte, and V. Praloran. The terapeptide AcSDKP, a physiological inhibitor of normal cell proliferation, reduces the S phase entry of continuous cell lines. Exp. Cell Res. 223:112-116 (1996).
25. Marshall, E., and B. I. Lord. Feedback inhibitors in normal and tumor tissues. Int. Rev. Cytol. 167:185-261 (1996).
26. Bonnet, D., R. Cesaire, F. Lemoine, M. Aoudjhane, A. Najman, and M. Guigon. The tetrapeptide AcSDKP, an inhibitor of the cell-cycle status for normal human hematopoietic progenitors, has no effect on leukemic cells. Exp. Hematol. 20:251-255 (1992).
27. Cashman, J. D., A. C. Eaves, and C. J. Eaves. The tetrapeptide AcSDKP specifically blocks the cycling of primitive normal but not leukemic progenitors in long-term culture: evidence for an indirect mechanism. Blood 84:1534-1542 (1994).
28. Bogden, A. E., P. Carde, E. Deschamps de Paillette, J.-P. Moreau, M. Tubiana, and E. Frindel. Amelioration of chemotherapy-induced toxicity by cotreatment with AcSDKP, a tetrapeptide inhibitor of hematopoietic stem cell proliferation. Ann. N Y Acad. Sci. 628:126-139 (1991).
29. Rieger, K.-J., N. Saez-Servent, M.-P. Papet, J. Wdzieczak-Bakala, J.-L. Morgat, J. Thierry, W. Voelter, and M. Lenfant. Involvement of human plasma angiotensin I-converting enzyme in the degradation of the hemoregulatory peptide N-acetyl seryl aspartyl lysyl proline. Biochem. J. 296: 1-6 (1993).
30. Comte, L., V. Lorgeot, A. Allégraud, Y. Le Meur, V. Praloran, and J.-C. Aldigier. Effets de l'enalapril sur le métabolisme de l'Ac-SDKP circulant et le taux des progéniteurs hématopoietiques circulants (abstract). Arch. Mal Coeur. 89:25 (1996).
31. Ezan, E., P. Carde, J. Le Kerneau, T. Ardouin, F. Thomas, F. Isnard, E. Deschamps de Paillette, and J.M. Grognet. Pharmacokinetics in healthy volunteers and patients of Nac-SDKP (Seraspenide), a negative regulator of hematopoiesis. Drug Metab. Dispos. 22:843-848 (1994).
32. Danilov, S., E. Jaspard, T. Churakova, H. Towbin, F. Savoie, L. Wei, and F. Alhenc-Gélas. Structure-function analysis of angiotensin I-converting enzyme using monoclonal antibodies. Selective inhibition of the amino-terminal active site. J. Biol. Chem. 269:26806-26814 (1994).
33. Shapiro, R., and J. Riordan. Inhibition of angiotensin converting enzyme: mechanism and substrate dependence. Biochemistry 23:5225-5233 (1984).